Clinical research progress of PD-1/PD-L1 inhibitor induction therapy in unresectable stage III non-small-cell lung cancer

DOI: 10.12201/bmr.202501.00025

•  

  Abstract: Non-small-cell lung cancer (NSCLC) is the most common malignant tumor, and its incidence and mortality rate rank first in China. For patients with unresectable locally advanced NSCLC, radical concurrent chemoradiotherapy(cCRT) has been the standard treatment for a long time. However, less than 30% of patients in China actually receive radical cCRT, and more patients adopt sequential CRT. Therefore, how to further optimize the mode of CRT has been a research hotspot. Based on the PACIFIC study and the GEMSTONE-301 study, giving immunotherapy as consolidation after CRT has become the standard treatment for patients with unresectable locally advanced NSCLC. However, about 1/4 of these patients still failed due to tumor progression or toxic reactions during CRT. In order to improve the efficacy of these patients, studies on immune-induction therapy has emerged. PD-1/PD-L1 inhibitors are the most commonly used immunotherapy in China. This paper summarized the latest clinical study on the immune-induction therapy model, such as immune-monotherapy(AFT-16 study), immunotherapy combined with chemotherapy (KEYNOTE-799 study, GASTO-1091 study), and immunotherapy combined with chemotherapy and anti-VEGFR-targeted therapy (GASTO-1086 study). These studies have preliminarily demonstrated the feasibility and safety of immune-induction therapy in patients with unresectable locally advanced NSCLC. However, since most of the current clinical studies are single-arm or retrospective studies, it still needs further support from more phase Ⅲ randomized controlled study data.

  Key words: Carcinoma, Non-Small-Cell Lung; Immune Checkpoint Inhibitors; Neoadjuvant Therapy; Radiotherapy.

  Submit time: 9 January 2025

  Copyright: The copyright holder for this preprint is the author/funder, who has granted biomedRxiv a license to display the preprint in perpetuity.
• html

• 图表

• 李娜, Luo bingqing. Clinical observation of microwave ablation combined with chemotherapy and PD-1 inhibitor for non-small cell lung cancer.. 2025. doi: 10.12201/bmr.202504.00054

  QIAN Yun. Adverse events associated with immune checkpoint inhibitors: clinical manifestations and mechanisms. 2025. doi: 10.12201/bmr.202502.00010

  CHENG Ke, XU Shucai. Progress in the treatment of blood hypercoagulability in patients with non-small cell lung cancer. 2025. doi: 10.12201/bmr.202506.00015

  Wang Huan, Ma Ying, Tian Jingnan, Lu Yi. Progress in the Diagnosis and Treatment of Immune Checkpoint Inhibitor-Associated Hypothyroidism from the Perspectives of Traditional Chinese and Western Medicine. 2025. doi: 10.12201/bmr.202505.00004

  Zhang Xinzhong. Research progress on folate receptor positive circulating tumor cells and the occurrence and development of non-small cell lung cancer. 2025. doi: 10.12201/bmr.202506.00024

  Li Ying, Wang Xiaofei, Lu Shengwei, Dong Danni, Zhang Jingfeng, Zheng Jianjun. CT Findings and Clinical Features of checkpoint Inhibitor-related pneumonitis. 2024. doi: 10.12201/bmr.202407.00008

  付思思. Construction and validation of Nomogram analysis model for nausea and vomiting after lobectomy in non-small cell lung cancer patients. 2025. doi: 10.12201/bmr.202507.00001

  HU Wei,. Clinical Efficacy of Penpulimab Combined Chemotherapy in Non-Squamous NSCLC. 2025. doi: 10.12201/bmr.202508.00045

  LiuHong, Zhou Xiaoyu, Zhang Qian, TanNianxi. Relationship between DNA methylation of RUNX3, P16 and DAPK gene promoters and chemosensitivity in non-small cell lung cancer. 2025. doi: 10.12201/bmr.202510.00045

  Houyu, Liyong, Zhouweixing, Liyaozaho, Lili. Progress in the study of cryoablation-induced immune effects and combined immunotherapy. 2025. doi: 10.12201/bmr.202503.00061

• ID	Submit time	Number	Download
  1	2024-12-23	10.12201/bmr.202501.00025V1	Download

• Public  Anonymous  To author only Submit Comments